Monoclonal antibodies in the treatment of colorectal cancer
详细信息 查看全文
- 作者：Veronese ; Maria Luisa ; O'Dwyer ; Peter J.
- 关键词：Monoclonal antibodies ; Colorectal cancer ; Edrecolomab ; Bevacizumab ; Cetuximab ; ABX-EGF ; EMD 72000
- 刊名：European Journal of Cancer
- 出版年：2004
- 出版时间：June, 2004
- 年：2004
- 卷：40
- 期：9
- 页码：1292-1301
- 全文大小：201 K
文摘
Monoclonal antibodies have been developed to target specific proteins involved in the development and progression of cancer. These reagents have the advantage of exquiste specificity, and as currently engineered, low toxicity. The impact monoclonal antibody therapy has recently been demonstrated in colorectal cancer, in which two pathways critical to carcinogenesis have been targeted. The targets are the epidermal growth factor receptor signaling pathway and angiogenesis. Antibodies directed to proteins in both pathways have shown significant activity especially in combination with chemotherapy, and studies in the adjuvant setting are in progress. We review the use of monoclonal antibodies in the treatment of colorectal cancer with particular attention to edrecolomab (Mab 17-1A), bevacizumab (Avastin), cetuximab (IMC-C225), ABX-EGF and EMD 72000. Additional compounds are in earlier stages of development, and the future of this approach in solid tumours is promising.